Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242223 | 0.89 | NPC1 (0.40) | LMNAALDH1A1KMT2AITGB3ITGA2B | |
| SCHEMBL3243834 | 0.88 | P2RX7 (0.39) | ALDH1A1MEN1KMT2AMAPK1P2RX7 | |
| SCHEMBL3237083 | 0.83 | POLB (0.42) | LMNAALDH1A1ITGB3ITGA2B | |
| SCHEMBL3232907 | 0.81 | ALDH1A1 (0.39) | LMNAALDH1A1ITGB3ITGA2B | |
| SCHEMBL3240097 | 0.80 | SLC6A9 (0.46) | LMNAALDH1A1 | |
| SCHEMBL3244796 | 0.80 | TAS1R3 (0.44) | LMNAALDH1A1KMT2AHSD11B1P2RX7 | |
| SCHEMBL3240092 | 0.80 | SLC6A9 (0.47) | ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL3236750 | 0.78 | ALDH1A1 (0.39) | LMNAALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL13631388 | 0.78 | RAB9A (0.51) | LMNAMEN1KMT2AGAA | |
| SCHEMBL3245182 | 0.78 | HPGD (0.45) | LMNAALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | LMNA 4449/4885ALDH1A1 1356/4885MEN1 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.